Abstract
We evaluated the replication and resistance patterns of human immunodeficiency virus (HIV) strains recovered from HIV-infected patients with non-Hodgkin lymphoma (NHL) who were receiving chemotherapy (CT) concomitant with highly active antiretroviral therapy (HAART). We analyzed virological response to HAART in 35 patients with HIV and NHL who were treated with a cyclophosphamide-doxorubicin-vincristine-prednisone chemotherapy regimen and HAART and the virological response in 26 HIV-infected patients with CD20 cell-positive NHL who were treated with rituximab and cyclophosphamide-doxorubin-etoposide therapy. Genotype and virtual phenotype analyses were performed at baseline and when virological failure occurred. Only 9 patients met the criteria for virological failure. Genotype and virtual phenotype analyses demonstrated that, during CT administration, new mutations might occur, but there were no significant changes in the preexisting resistance patterns. Our data show that combination therapy consisting of CT and HAART is feasible and that the virological response can be maintained in the majority of patients receiving this treatment.
| Original language | English |
|---|---|
| Pages (from-to) | 820-827 |
| Number of pages | 8 |
| Journal | Clinical Infectious Diseases |
| Volume | 37 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Sep 15 2003 |
Fingerprint
ASJC Scopus subject areas
- Immunology
Cite this
Impact of concomitant antiblastic chemotherapy and highly active antiretroviral therapy on human immunodeficiency virus (HIV) viremia and genotyping in HIV-infected patients with non-Hodgkin lymphoma. / Simonelli, Cecilia; Zanussi, Stefania; Cinelli, Roberta; Dal Maso, Luigino; Di Gennaro, Giampiero; D'Andrea, Monica; Nasti, Guglielmo; Spina, Michele; Vaccher, Emanuela; De Paoli, Paolo; Tirelli, Umberto.
In: Clinical Infectious Diseases, Vol. 37, No. 6, 15.09.2003, p. 820-827.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Impact of concomitant antiblastic chemotherapy and highly active antiretroviral therapy on human immunodeficiency virus (HIV) viremia and genotyping in HIV-infected patients with non-Hodgkin lymphoma
AU - Simonelli, Cecilia
AU - Zanussi, Stefania
AU - Cinelli, Roberta
AU - Dal Maso, Luigino
AU - Di Gennaro, Giampiero
AU - D'Andrea, Monica
AU - Nasti, Guglielmo
AU - Spina, Michele
AU - Vaccher, Emanuela
AU - De Paoli, Paolo
AU - Tirelli, Umberto
PY - 2003/9/15
Y1 - 2003/9/15
N2 - We evaluated the replication and resistance patterns of human immunodeficiency virus (HIV) strains recovered from HIV-infected patients with non-Hodgkin lymphoma (NHL) who were receiving chemotherapy (CT) concomitant with highly active antiretroviral therapy (HAART). We analyzed virological response to HAART in 35 patients with HIV and NHL who were treated with a cyclophosphamide-doxorubicin-vincristine-prednisone chemotherapy regimen and HAART and the virological response in 26 HIV-infected patients with CD20 cell-positive NHL who were treated with rituximab and cyclophosphamide-doxorubin-etoposide therapy. Genotype and virtual phenotype analyses were performed at baseline and when virological failure occurred. Only 9 patients met the criteria for virological failure. Genotype and virtual phenotype analyses demonstrated that, during CT administration, new mutations might occur, but there were no significant changes in the preexisting resistance patterns. Our data show that combination therapy consisting of CT and HAART is feasible and that the virological response can be maintained in the majority of patients receiving this treatment.
AB - We evaluated the replication and resistance patterns of human immunodeficiency virus (HIV) strains recovered from HIV-infected patients with non-Hodgkin lymphoma (NHL) who were receiving chemotherapy (CT) concomitant with highly active antiretroviral therapy (HAART). We analyzed virological response to HAART in 35 patients with HIV and NHL who were treated with a cyclophosphamide-doxorubicin-vincristine-prednisone chemotherapy regimen and HAART and the virological response in 26 HIV-infected patients with CD20 cell-positive NHL who were treated with rituximab and cyclophosphamide-doxorubin-etoposide therapy. Genotype and virtual phenotype analyses were performed at baseline and when virological failure occurred. Only 9 patients met the criteria for virological failure. Genotype and virtual phenotype analyses demonstrated that, during CT administration, new mutations might occur, but there were no significant changes in the preexisting resistance patterns. Our data show that combination therapy consisting of CT and HAART is feasible and that the virological response can be maintained in the majority of patients receiving this treatment.
UR - http://www.scopus.com/inward/record.url?scp=0141453197&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0141453197&partnerID=8YFLogxK
U2 - 10.1086/377204
DO - 10.1086/377204
M3 - Article
VL - 37
SP - 820
EP - 827
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
SN - 1058-4838
IS - 6
ER -